Ras oncogene mutations in benign and malignant thyroid neoplasms

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Tumorigenesis involves genetic alterations.
• Ras gene mutations are implicated in various human cancers, including thyroid cancer.

Purpose of the Study:

• To investigate the frequency of activating ras oncogene mutations (codons 12, 13, and 61) in benign and malignant thyroid neoplasms.
• To explore potential associations between ras mutations and clinical outcomes, such as bone metastases in follicular carcinoma.

Main Methods:

• Genomic DNA was extracted from thyroid tissue samples (n=38), including follicular adenomas, follicular carcinomas, and papillary carcinomas.
• DNA was amplified using the polymerase chain reaction (PCR).
• Mutations were screened using oligonucleotide-specific hybridization.

Main Results:

• No ras mutations were detected in follicular adenomas (n=9).
• Ras mutations were found in 2 of 14 follicular carcinomas (N-ras 61), both associated with bone metastases.
• One of 15 papillary carcinomas harbored a ras mutation (H-ras 12).
• Overall, ras mutations were relatively infrequent in the studied thyroid neoplasms.

Conclusions:

• Ras mutations appear to be uncommon in both benign and malignant thyroid neoplasms.
• The N-ras 61 mutation may be associated with aggressive follicular thyroid cancer, but larger studies are needed.
• Further research is required to confirm the role of ras mutations in thyroid cancer progression and clinical behavior.